The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Current use of bisphosphonates in oncology. International Bone and Cancer Study Group.
Abstract
PURPOSE: The purpose of this article is to review the recent data on bisphosphonate use in oncology and to provide some guidelines on the indications for their use in cancer patients. DESIGN: The group consensus reached by experts on the rationale for the use of bisphosphonates in cancer patients and their current indications for the treatment of tumor-induced hypercalcemia and metastatic bone pain in advanced disease and for the prevention of the complications of multiple myeloma and of metastatic bone disease are reviewed. RESULTS: Bisphosphonates are potent inhibitors of tumor-induced osteoclast-mediated bone resorption. They now constitute the standard treatment for cancer hypercalcemia, for which we recommend a dose of 1,500 mg of clodronate or 90 mg of pamidronate; the latter compound is more potent and has a longer lasting effect. Intravenous bisphosphonates exert clinically relevant analgesic effects in patients with metastatic bone pain. Regular pamidronate infusions can also achieve a partial objective response by conventional International Union Against Cancer criteria and enhance the objective response rate to chemotherapy. In breast cancer, the prolonged administration of oral clodronate 1,600 mg daily reduces the frequency of morbid skeletal events by more than one fourth, whereas monthly pamidronate infusions of 90 mg for only 1 year in addition to chemotherapy reduce by more than one third the frequency of all skeletal-related events. The use of bisphosphonates to prevent bone metastases remains experimental. Last, bisphosphonates in addition to chemotherapy are superior to chemotherapy alone in patients with stages II and III multiple myeloma and can reduce the skeletal morbidity rate by approximately one half. CONCLUSION: Bisphosphonate use is a major therapeutic advance in the management of the skeletal morbidity caused by metastatic breast cancer or multiple myeloma, although many questions remain unanswered, notably regarding the optimal selection of patients and the duration of treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Roodman, G. D. (2004) · New England Journal of Medicine · doi:10.1056/nejmra030831 · Cited by 2,755
Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma
Berenson, J. R., Lichtenstein, A., Porter, L., Dimopoulos, M. A., Bordoni, R., George, S., Lipton, A., Keller, A., Ballester, O., Kovacs, M. J., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602223340802 · Cited by 1,081
Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo
Hughes, D. E., Wright, K. R., Uy, H. L., Sasaki, A., Yoneda, T., Roodman, D. G., Mundy, G. R., & Dr. Boyce, B. F. (1995) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650101008 · Cited by 1,040
Self-citationHortobagyi, G. N., Theriault, R. L., Porter, L., Blayney, D., Lipton, A., Sinoff, C., Wheeler, H., Simeone, J. F., Seaman, J., Knight, R. D., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199612123352401 · Cited by 1,026
Sato, M., Grasser, W., Endo, N., Akins, R., Simmons, H., Thompson, D. D., Golub, E., & Rodan, G. A. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115539 · Cited by 1,004
Paterson, A. H., Powles, T. J., Kanis, J. A., McCloskey, E., Hanson, J., & Ashley, S. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.1.59 · Cited by 557
Self-citationPreclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound
Green, J. R., Müller, K., & Jaeggi, K. A. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090521 · Cited by 415
Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma
Lahtinen, R., Laakso, M., Palva, I., Elomaa, I., & Virkkunen, P. (1992) · The Lancet · doi:10.1016/0140-6736(92)93075-x · Cited by 385
Boissier, S., Magnetto, S., Frappart, L., Cuzin, B., Ebetino, F. H., Delmas, P. D., & Clézardin, P. (1997) · PubMed · Cited by 343
Self-citationInsulin-like growth factor receptor expression and function in human breast cancer.
Cullen, K. J., Yee, D., Sly, W. S., Perdue, J. F., Hampton, B., Lippman, M. E., & Rosen, N. X. (1990) · PubMed · Cited by 319
Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro.
van der Pluijm, G., Vloedgraven, H., van Beek, E., van der Wee-Pals, L., Löwik, C., & Papapoulos, S. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118841 · Cited by 305
Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption
Vitte, C. (1996) · Endocrinology · doi:10.1210/en.137.6.2324 · Cited by 299
GRILL, V., HO, P., BODY, J. J., JOHANSON, N., LEE, S. C., KUKREJA, S. C., MOSELEY, J. M., & MARTIN, T. J. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-73-6-1309 · Cited by 292
Self-citationDelmas, P. D., Balena, R., Confravreux, E., Hardouin, C., Hardy, P., & Bremond, A. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.3.955 · Cited by 278
Self-citationConte, P. F., Latreille, J., Mauriac, L., Calabresi, F., Santos, R., Campos, D., Bonneterre, J., Francini, G., & Ford, J. M. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.9.2552 · Cited by 268
Yoneda, T., Sasaki, A., Dunstan, C., Williams, P. J., Bauss, F., De Clerck, Y. A., & Mundy, G. R. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119435 · Cited by 247
Self-citationOsteolytic bone metastasis in breast cancer
Yoneda, T., Sasaki, A., & Mundy, G. R. (1994) · Breast Cancer Research and Treatment · doi:10.1007/bf00666208 · Cited by 246
Self-citationClodronate decreases the frequency of skeletal metastases in women with breast cancer
Kanis, J. A., Powles, T., Paterson, A. H. G., McCloskey, E. V., & Ashley, S. (1996) · Bone · doi:10.1016/s8756-3282(96)00285-2 · Cited by 224
Self-citationPalliative pamidronate treatment in patients with bone metastases from breast cancer.
van Holten-Verzantvoort, A. T., Kroon, H. M., Bijvoet, O. L., Cleton, F. J., Beex, L. V., Blijham, G., Hermans, J., Neijt, J. P., Papapoulos, S. E., & Sleeboom, H. P. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.3.491 · Cited by 196
Effect of daily etidronate on the osteolysis of multiple myeloma.
Belch, A. R., Bergsagel, D. E., Wilson, K., O'Reilly, S., Wilson, J., Sutton, D., Pater, J., Johnston, D., & Zee, B. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.8.1397 · Cited by 178
High-dose intravenous pamidronate for metastatic bone pain
Purohit, O., Anthony, C., Radstone, C., Owen, J., & Coleman, R. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.344 · Cited by 158
Vargas, S. J., Gillespie, M. T., Powell, G. J., Southby, J., Danks, J. A., Moseley, J. M., & Martin, J. T. (1992) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650070814 · Cited by 155
Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia
Ralston, S. H., Thiébaud, D., Herrmann, Z., Steinhauer, E., Thurlimann, B. J. K., Walls, J., Lichinitser, M., Rizzoll, R., Hagberg, H., Huss, H., et al. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.48 · Cited by 129
Self-citationDelmas, P. D., CHARHON, S. A., Chapuy, M. C., Vignon, E. P., Briançon, D., Edouard, C. M., & Meunier, P. J. (1982) · Metabolic Bone Disease and Related Research · doi:10.1016/0221-8747(82)90013-3 · Cited by 128
Self-citationColeman, R., Woll, P. J., Miles, M., Scrivener, W., & Rubens, R. (1988) · British Journal of Cancer · doi:10.1038/bjc.1988.272 · Cited by 128
Self-citationPecherstorfer, M., Herrmann, Z., Body, J., Manegold, C., Degardin, M., Clemens, M., Thurlimann, B. J. K., Tubiana-Hulin, M., Steinhauer, E. U., Eijkeren, M. V., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.1.268 · Cited by 124
Self-citationZimolo, Z., Wesolowski, G. A., & Rodan, G. A. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118283 · Cited by 110
Ernst, D. S., Brasher, P. M. A., Hagen, N. A., Paterson, A. H. G., MacDonald, R. N., & Bruera, E. D. (1997) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(97)00075-4 · Cited by 105
Self-citationThiébaud, D., Jaeger, P., Jacquet, A. F., & Burckhardt, P. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.5.762 · Cited by 104
Self-citationEffect of oral clodronate on metastatic bone pain: a double-blind, placebo-controlled study.
Robertson, A. G., Reed, N. S., & Ralston, S. H. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.9.2427 · Cited by 99
Singer, F. R. (1991) · Archives of Internal Medicine · doi:10.1001/archinte.1991.00400030039007 · Cited by 93
New bisphosphonates in osteoporosis
Fleisch, H. A. (1993) · Osteoporosis International · doi:10.1007/bf01623222 · Cited by 91
Self-citationUse of bisphosphonates in cancer patients
Body, J., Coleman, R. E., & Piccart, M. J. (1996) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(96)90020-1 · Cited by 89
Self-citationEffective treatment of malignant hypercalcaemia with a single intravenous infusion of clodronate
O'Rourke, N., McCloskey, E. V., Vasikaran, S. D., EYRES, K. S., Fern, D. L., & Kanis, J. A. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.102 · Cited by 77
Self-citationTreatment of bone metastases from breast cancer and myeloma with pamidronate.
Thiébaud, D., Leyvraz, S., von Fliedner, V., Perey, L., Cornu, P., Thiébaud, S., & Burckhardt, P. (1991) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(91)90056-j · Cited by 75
Self-citationMerlini, G., Parrinello, G. A., Piccinini, L., Crema, F., Fiorentini, M., Riccardi, A., Pavesi, F., Novazzi, F., Silingardi, V., & Ascari, E. (1990) · Hematological Oncology · doi:10.1002/hon.2900080104 · Cited by 67
Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injection
Pecherstorfer, M., Ludwig, H., Schlosser, K., Buck, S., Huss, H., & Body, J. (1996) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650110506 · Cited by 64
Self-citationWalls, J., RATCLIFFE, W. A., Howell, A., & Bundred, N. J. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.270 · Cited by 58
Heim, M., Clemens, M. R., Queißer, W., Pecherstorfer, M., Boewer, C., Herold, M. J., Franke, A., Herrmann, Z., Loose, R., & Edler, L. (2009) · Onkologie · doi:10.1159/000218633 · Cited by 52
Dodwell, D. J., Abbas, S. K., Morton, A. R., & Howell, A. (1991) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(91)90431-c · Cited by 47
Effects of oral clodronate on bone mineral density in patients with relapsing breast cancer
Rizzoli, R. (1996) · Bone · doi:10.1016/8756-3282(96)00075-0 · Cited by 31
Medical management of hypercalcaemia.
Ralston, S. H. (1992) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1992.tb04101.x · Cited by 31
Tyrrell, C., Bruning, P. F., May-Levin, F., Rose, C. S., Mauriac, L., Soukoup, M., Fargeot, P., & Howell, A. (1994) · Research Explorer (The University of Manchester) · Cited by 14
Cascinu, S., Casadei, V., Ferro, E. D., Alessandroni, P., & Catalano, G. (1996) · Supportive Care in Cancer · doi:10.1007/bf01769872 · Cited by 11
Cited by
Metastatic bone disease: clinical features, pathophysiology and treatment strategies
Coleman, R. E. (2001) · Cancer Treatment Reviews · doi:10.1053/ctrv.2000.0210 · Cited by 1,920
Skeletal complications of malignancy
Coleman, R. E. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19971015)80:8+<1588::aid-cncr9>3.0.co;2-g · Cited by 1,502
Berenson, J. R., Hillner, B. E., Kyle, R. A., Anderson, K., Lipton, A., Yee, G. C., & Biermann, J. S. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.06.037 · Cited by 542
Self-citationBody, J.-J., Diel, I. J., Lichinitser, M. R., Kreuser, E. D., Dornoff, W., Gorbunova, V. A., Budde, M., & Bergström, B. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg367 · Cited by 413
Self-citationAmerican Society of Clinical Oncology Guideline on the Role of Bisphosphonates in Breast Cancer
Hillner, B. E., Ingle, J. N., Berenson, J. R., Janjan, N. A., Albain, K. S., Lipton, A., Yee, G., Biermann, J. S., Chlebowski, R. T., Pfister, D. G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.6.1378 · Cited by 383
Metadata
- Authors
- Body, J. J., Bartl, R., Burckhardt, P., Delmas, P. D., Diel, I. J., Fleisch, H., Kanis, J. A., Kyle, R. A., Mundy, G. R., Paterson, A. H., & Rubens, R. D.
- Venue
- Journal of Clinical Oncology
- Published
- 1998-12
- Volume
- 16
- Issue
- 12
- Pages
- 3890-3899
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1937662086
- Cited by
- 359
- References
- 45
- FWCI
- 10.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.